London, April 2026 - The Innovators Club, a flagship network accelerator programme run by the Science Entrepreneur Club (SEC), has unveiled its sixth cohort, bringing together eight promising life science start-ups.
The selected ventures will participate in a 10-week, fee-free and equity-free programme running from early April to mid-June. Throughout the programme, founders will engage in expert-led sessions covering areas such as intellectual property, investment fundraising, grant writing, and pitching. In addition, the cohort will gain access to informal networking events, one-to-one no-detriment meetings with investors, specialist service providers, a custom-written article by SEC’s Science Writers, and an opportunity to pitch to the BioCapital Network - the UK’s largest life science investor community, which now includes over 500 members.
At the end of the programme, the Cohort VI companies will all be in with the chance of winning a prize package which includes a 12-month virtual membership at London BioScience Innovation Centre (LBIC), right in the heart of King’s Cross Knowledge Quarter, alongside a series of other benefits kindly donated by programme supporters.
Each company will become part of a tight-knit community of life science founders, all navigating the shared challenges of building early-stage ventures. After completing the programme, Cohort VI participants will continue their journey as members of the BioEntrepreneur Club, with ongoing backing from the SEC team. They will join an accomplished alumni network, where 28 companies from previous cohorts have collectively secured over £65 million in funding.
Championing diversity remains a core priority for the programme, and we are proud that across all six cohorts to date, half of the companies have had a woman founder or co-founder.
Cohort VI is powered by Gold sponsors Marks & Clerk (M&C).
With a highly skilled team of life science experts, M&C offers deep expertise across all life science technical fields, including pharmaceuticals, agri-tech, animal health, diagnostics, and more. They have combined knowledge across the firm to apply expertise in emerging fields such as AI and sustainable technologies, enabling them to be positioned at the forefront of innovation in the life sciences sector.
Co-Founders: Zayd Lakhi and Isaac Gállego
By combining proprietary enzymatic chemistry, intelligent sequence design algorithms, and plugging into existing, widely available automation infrastructure, AmpliSynth eliminates the 3 week+ turnaround of outsourced DNA synthesis and provides same-day, instant access to gene synthesis. Our vision is to take biotech from monthly, non-cyclical "eureka" moments, to daily iterative cycles.
Co-Founders: James Gavin, Andrew Devitt and Ivana Milic
EVolution Therapeutics is an innovative biotech spin-out with a visionary mission to revolutionise the treatment of inflammatory diseases through our mRNA–nanoparticle therapeutics, starting with our pioneering work in wound healing.
Co-Founders: Dan Hardy and Victoria Legh-Land
Microsol is a Bristol-based platform technology company transforming inhaled drug development to de-risk and accelerate development for pharmaceutical companies and to produce better products for patients. We combine predictive simulations with individual aerosol particle measurements to enable earlier, higher-confidence formulation decisions, resulting in faster, optimised and cost-effective inhaled product development.
Co-Founders: Tom Swift and Steven Rimmer
Molecular Titans is a UK biotechnology company developing smart, water‑soluble polymer technologies for rapid, point‑of‑use detection of infectious microbes. Their capture‑and‑release nanomaterials enable fast organism identification outside laboratories, supporting better clinical decisions and antibiotic stewardship.
Founder: Lisa Dratva
needle.bio is creating a new category in immunomics by turning billions of T cell receptor sequences and single cell measurements into a functional map of human immunity, using AI and targeted experiments to uncover drivers of immune protection, pathology, and treatment response at scale.
Stealth Company
The company delivers quantum-accurate chemical reaction simulations by combining machine learning with first-principals quantum mechanics, removing the cost and speed bottlenecks which limits the utility of traditional quantum simulations. This lets drug, specialty chemical, and enzyme R&D teams computationally triage thousands of reactive candidates with experimental accuracy, cutting wet-lab screening costs and compressing development timelines.
Founder: Ilinca Georgescu
Trem is a healthtech company developing a validated digital biomarker platform for Essential Tremor - the world's most common movement disorder, affecting an estimated 80-100 million people globally. By linking to existing wearables, Trem enables objective, continuous measurement of tremor severity, transforming a condition historically assessed through subjective clinical observation into a data-driven, remotely monitorable experience. Trem's technology supports clinical trials, neurological care pathways, and patient self-management.
Founder: Kiren Baines-Mortimore
Valaya Bio is developing an RNAi therapeutics platform to treat age-related degenerative diseases, starting with Parkinson’s. We target clinically validated master regulators to restore dysfunctional cellular pathways, including mitochondrial function, autophagy, and inflammation. Our approach combines precision oligonucleotide technology with brain-shuttle delivery to enable scalable, disease-modifying therapies beyond single-pathway interventions.
Sign up for our monthly newsletter of upcoming events, recently published insights, member news and SEC updates.
.jpg)
